MCID: MNT001
MIFTS: 70

Mantle Cell Lymphoma malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mantle Cell Lymphoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 26GTR, 29ICD10, 30ICD10 via Orphanet, 34LifeMap Discovery®, 39MESH via Orphanet, 47NIH Rare Diseases, 49Novoseek, 53Orphanet, 67UMLS
See all MalaCards sources

Aliases & Descriptions for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 34 11 47 53 13
Lymphoma, Mantle Cell 47 26 12
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 67
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 67
Lymphocytic Choriomeningitis 67
 
Lymphoma Mantle-Cell 49
Mantle Zone Lymphoma 53
Mcl 53
Lcm 53

Characteristics:

Orphanet epidemiological data:

53
mantle cell lymphoma:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult

Classifications:



External Ids:

Disease Ontology11 DOID:0050746
Orphanet53 ORPHA52416
MESH via Orphanet39 D020522
ICD10 via Orphanet30 C83.1
ICD1029 C83.1

Summaries for Mantle Cell Lymphoma

About this section
Disease Ontology:11 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

MalaCards based summary: Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to plasmacytoma and prostate cancer, and has symptoms including lymphadenopathy, hematological neoplasm and splenomegaly. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways are Inhibition of Ribosome Biogenesis by p14(ARF) and Regulation of Telomerase. Affiliated tissues include b cells, bone and bone marrow, and related mouse phenotypes are respiratory system and embryo.

Wikipedia:70 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

About this section

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 192)
idRelated DiseaseScoreTop Affiliating Genes
1plasmacytoma30.4CCND1, MYC, TP53
2prostate cancer29.5ATM, BCL2, CCND1, EZH2, MCL1, MDM2
3lymphoma11.2
4lysosomal storage disease10.9BCL2, CCND1
5chromosome 7p duplication10.8MDM2, TP53
6bladder verrucous squamous cell carcinoma10.8CCND1, MDM2, TP53
7bile duct disease10.8ATM, MDM2, TP53
8novak syndrome10.8BCL2, CCND1, TP53
9stampe sorensen syndrome10.8BCL2, MDM2, TP53
10hemochromatosis type 210.8CCND1, MTOR, MYC
11progesterone-receptor positive breast cancer10.7CCND1, MTOR, TP53
12trachea squamous cell carcinoma10.7CD5, MME
13solitary plasmacytoma of chest wall10.7CCND1, CD5, MYC
14leukoencephalopathy palmoplantar keratoderma10.7CCND1, IGH, MYC
15arrhythmogenic right ventricular cardiomyopathy10.7CCND1, MYC, TP53
16brittle bone syndrome lethal type10.7ATM, CCND1, TP53
17cerebellar vermis medulloblastoma10.7CCND1, MYC, TP53
18peritoneal serous adenocarcinoma10.7CCND1, MYC, TP53
19mixed extragonadal germ cell cancer10.7CCND1, MDM2, TP53
20integumentary system cancer10.7BMI1, CCND1, TP53
21pasli disease10.7MDM2, TP53
22spinal cord primitive neuroectodermal neoplasm10.7CCND1, MYC, TP53
23chromosome 13q14 deletion syndrome10.7ATM, BCL2, CD5, MCL1
24gray zone lymphoma10.7CCND1, CD5, MME
25trachea sarcoma10.7CCND1, MYC, TP53
26hodgkin's granuloma10.7BMI1, CCND1, TP53
27clear cell acanthoma10.7ATM, CD5, MYC, TP53
28uterine body mixed cancer10.7BCL2, MME, TP53
29nasopharyngeal carcinoma10.7ATM, BCL2, MDM2, TP53
30primary cutaneous unspecified peripheral t-cell lymphoma10.7BCL2, BCL6
31plasma protein metabolism disease10.7CCND1, MYC, TP53
32esophagus lymphoma10.7CCND1, MDM2, MYC, TP53
33alcoholic hepatitis10.7CCND2, PMAIP1, TP53
34giant cell glioblastoma10.7CCND1, MDM2, MTOR, TP53
35encapsulated thymoma10.7CD5, MTOR, TP53
36epithelioid type angiomyolipoma10.6MME, MTOR, TP53
37atrial standstill10.6BCL2, MDM2, TP53
38dysostosis10.6CCND1, MYC, TP53
39histidine metabolism disease10.6BMI1, CCND1, MYC, TP53
40congenital myasthenic syndrome10.6BCL6, CD5, TP53
41gliomatosis peritonei10.6MDM2, MTOR, MYC, TP53
42gliosarcoma10.6MDM2, MTOR, MYC, TP53
43ladd syndrome10.6BCL2, MDM2, MYC, TP53
44brown-vialetto-van laere syndrome10.6CCND1, MYC, TP53
45lung cancer susceptibility 410.6BCL2, BCL6, IGH
46monkeypox10.6BCL2, CD5
47gallbladder papillomatosis10.6CCND1, MYC, TP53
48myopathy10.6CCND1, MME, TP53
49multicentric reticulohistiocytosis10.6CD19, CD5, MME
50benign angiitis of the central nervous system10.6CD19, CD5, MYC, TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to mantle cell lymphoma

Symptoms for Mantle Cell Lymphoma

About this section

Human phenotypes related to Mantle Cell Lymphoma:

 63 53 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy63 53 hallmark (90%) Very frequent (99-80%) HP:0002716
2 hematological neoplasm63 hallmark (90%) HP:0004377
3 splenomegaly63 53 typical (50%) Frequent (79-30%) HP:0001744
4 weight loss63 53 typical (50%) Frequent (79-30%) HP:0001824
5 anorexia63 53 typical (50%) Frequent (79-30%) HP:0002039
6 abnormality of bone marrow cell morphology53 Frequent (79-30%)
7 abnormality of the gastrointestinal tract53 Occasional (29-5%)
8 fatigue53 Frequent (79-30%)
9 fever53 Frequent (79-30%)
10 b-cell lymphoma53 Very frequent (99-80%)

Drugs & Therapeutics for Mantle Cell Lymphoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Imbruvica16 43 IBRUTINIB Pharmacyclics November of 2013/ February 2014
FDA Label: Imbruvica
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:16 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenström’s macroglobulinemia (WM) (1.4).
DrugBank Targets:14 1. Tyrosine-protein kinase BTK
Mechanism of Action:16 
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’srole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
2
Revlimid16 43 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
3
Velcade16 43 BORTEZOMIB Millennium Pharmaceuticals May 2003
FDA Label: Velcade
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:16 VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:14 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:16 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 492)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
2
rituximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
3
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
4
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
5
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 1, Phase 2208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
6
Cytarabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11093147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
7
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 19042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
8
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
9
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
11
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
12
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
13
ThiotepaapprovedPhase 4, Phase 2, Phase 3, Phase 121652-24-45453
Synonyms:
 
Thioplex
14
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
15
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
16Gastrointestinal AgentsPhase 4, Phase 3, Phase 1, Phase 28109
17Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
18glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14920
19Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112778
20Dexamethasone acetatePhase 4, Phase 3, Phase 1, Phase 220841177-87-3
21
protease inhibitorsPhase 4, Phase 3, Phase 1, Phase 25320
Synonyms:
 
protease inhibitors
22Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14945
23Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 222776
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
25Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
26HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113979
27HIV Protease InhibitorsPhase 4, Phase 3, Phase 1, Phase 25319
28Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11232
29Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14072
30Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
31Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
32AntiemeticsPhase 4, Phase 3, Phase 1, Phase 23888
33Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14143
34Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 1, Phase 22084
35Antilymphocyte SerumPhase 4, Phase 2, Phase 3, Phase 1399
36Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
37Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
38Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
39Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
40Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 19732
41Autonomic AgentsPhase 4, Phase 3, Phase 1, Phase 29774
42BB 1101Phase 4, Phase 3, Phase 1, Phase 22084
43Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110355
44Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15420
45Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17171
46Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15407
47Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 15498
48AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111774
49
Ketamineapproved, vet_approvedPhase 35286740-88-13821
Synonyms:
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(-)-Ketamine
(S)-(-)-Ketamine
(S)-Ketamine
(±)-ketamine
100477-72-3
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Calypsol
Cetamina
Cetamina [INN-Spanish]
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
 
DL-ketamine
DivK1c_000217
EINECS 229-804-1
Esketamine
Green
IDI1_000217
KBio1_000217
KETAMINE
KETAMINE HCL
Ketaject
Ketalar
Ketalar base
Ketamina
Ketamine (INN)
Ketamine Base
Ketamine HCL
Ketamine [INN:BAN]
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketoject
Ketolar
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
Special k
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
dl-Ketamine
ketamine
l-Ketamine
50
LenalidomideapprovedPhase 3, Phase 1, Phase 2718191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide

Interventional clinical trials:

(show top 50)    (show all 927)
idNameStatusNCT IDPhase
1Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
2EDOCH Alternating With DHAP for New Diagnosed Younger MCLRecruitingNCT02858804Phase 4
3Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell LymphomaRecruitingNCT01180049Phase 4
4An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT01833039Phase 4
5Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCLUnknown statusNCT00209209Phase 3
6Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell LymphomaUnknown statusNCT00016887Phase 3
7Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLUnknown statusNCT01449344Phase 3
8Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell LymphomaUnknown statusNCT00641095Phase 3
9Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLUnknown statusNCT00209222Phase 3
10Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaUnknown statusNCT00003337Phase 3
11Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaUnknown statusNCT00003338Phase 2, Phase 3
12Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaUnknown statusNCT00052936Phase 3
13Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's LymphomaUnknown statusNCT00053768Phase 3
14Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaUnknown statusNCT00028717Phase 3
15Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeUnknown statusNCT00002989Phase 3
16Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaUnknown statusNCT00020865Phase 3
17Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaUnknown statusNCT00445497Phase 3
18Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
19Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaUnknown statusNCT00003924Phase 3
20Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's DiseaseUnknown statusNCT00002987Phase 3
21Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaCompletedNCT00003280Phase 3
22Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3
23Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3
24Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedNCT01456351Phase 3
25Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceCompletedNCT00921414Phase 3
26Bendamustine Plus Rituximab Versus CHOP Plus RituximabCompletedNCT00991211Phase 3
27A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's LymphomaCompletedNCT00269113Phase 3
28Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
29Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00005590Phase 3
30Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
31Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00278421Phase 3
32Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00278408Phase 3
33Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountCompletedNCT00003805Phase 3
34St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
35Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
36Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3
37Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
38Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
39American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3
40Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3
41Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00004112Phase 3
42Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
43Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3
44Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
45Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
46Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell TransplantationCompletedNCT00014391Phase 3
47Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow TransplantationCompletedNCT00003883Phase 3
48Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell TransplantCompletedNCT00305851Phase 3
49Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell TransplantationCompletedNCT00004230Phase 3
50Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00045292Phase 3

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Mantle Cell Lymphoma

About this section

Genetic tests related to Mantle Cell Lymphoma:

id Genetic test Affiliating Genes
1 Mantle Cell Lymphoma26

Anatomical Context for Mantle Cell Lymphoma

About this section

MalaCards organs/tissues related to Mantle Cell Lymphoma:

35
B cells, Bone, Bone marrow, T cells, Liver, Kidney, Colon

Animal Models for Mantle Cell Lymphoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

40 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053889.8BCL2, BCL6, CCND1, CCND3, MTOR, SOX11
2MP:00053809.8ATM, EZH2, MCL1, MDM2, MTOR, MYC
3MP:00053899.5ATM, BCL2, BCL6, CCND1, CCND2, MCL1
4MP:00053709.5BCL6, CCND2, CCND3, CD19, MDM2, MME
5MP:00020069.4ATM, BCL2, BTK, CCND1, CCND3, CD19
6MP:00053819.3BCL2, BTK, CCND1, CD19, MDM2, MYC
7MP:00107719.1ATM, BCL2, BTK, CCND1, CD19, EZH2
8MP:00053869.0ATM, BCL2, CCND1, CCND2, CCND3, CD19
9MP:00053799.0ATM, BCL2, BCL6, CCND1, CCND2, CCND3
10MP:00036319.0ATM, BCL2, CCND1, CCND2, CD19, EZH2
11MP:00053848.9ATM, BCL2, BCL6, BTK, CCND1, CD19
12MP:00028738.9BCL6, CCND1, CCND3, CD19, CD5, EZH2
13MP:00053788.6ATM, BCL2, BCL6, BTK, CCND1, CCND3
14MP:00053858.5BCL2, BCL6, CCND1, CCND2, CCND3, CD19
15MP:00107688.4ATM, BCL2, BCL6, BTK, CCND1, CCND2
16MP:00053978.3ATM, BCL2, BCL6, BTK, CCND1, CCND2
17MP:00053878.2ATM, BCL2, BCL6, BTK, CCND1, CCND2
18MP:00053768.1ATM, BCL2, BCL6, BTK, CCND1, CCND2

Publications for Mantle Cell Lymphoma

About this section

Articles related to Mantle Cell Lymphoma:

(show top 50)    (show all 995)
idTitleAuthorsYear
1
Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. (27140422)
2016
2
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. (27616553)
2016
3
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. (27087288)
2016
4
COUNTERPOINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma. (27987197)
2016
5
Multiple cutaneous metastases as the first sign of mantle cell lymphoma associated with multiple HPVA 52-positive squamous cell carcinomas of the skin. (27550714)
2016
6
Identification of miR-15b as a transformation-related factor in mantle cell lymphoma. (26676972)
2016
7
Validation of R-MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma. (27125335)
2016
8
Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm. (26461009)
2015
9
Ibrutinib approved for mantle cell lymphoma. (24402946)
2014
10
Mantle cell lymphoma masked by posttraumatic pancreatic hematoma. (25409048)
2014
11
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. (23730878)
2013
12
Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus. (23137523)
2013
13
MicroRNAs in mantle cell lymphoma. (23339447)
2013
14
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. (23940282)
2013
15
A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. (24107828)
2013
16
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. (22475365)
2012
17
Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? (22550404)
2012
18
Scoring systems in mantle cell lymphoma: a critical point of view. (21915995)
2012
19
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. (22185662)
2012
20
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. (22000823)
2012
21
Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. (22170090)
2012
22
Mantle cell lymphoma involvement of the pleura and tuberculous pleurisy with pulmonary tuberculosis: a case report and literature review. (21968964)
2012
23
Multiple lymphomatous polyposis of intestine as presentation of mantle cell lymphoma. (23130858)
2012
24
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. (21067447)
2011
25
Chlorambucil in indolent mantle cell lymphoma--just another old drug for a new disease? (21271863)
2011
26
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. (21750224)
2011
27
Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. (21850989)
2011
28
Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. (21603610)
2011
29
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. (21133727)
2011
30
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. (20647473)
2010
31
SOX11 expression in mantle cell lymphoma. (20919851)
2010
32
Mantle cell lymphoma of orbit in a middle aged female--a case report. (21744774)
2010
33
Hyperinfection by Strongyloides stercoralis probably associated with Rituximab in a patient with mantle cell lymphoma and hyper eosinophilia. (21748232)
2010
34
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. (19723646)
2009
35
Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. (17934069)
2008
36
Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. (16155021)
2005
37
Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. (16219581)
2005
38
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. (16123218)
2005
39
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. (14630827)
2004
40
Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. (12733111)
2003
41
Clinicopathologic features of mantle cell lymphoma and the significance of cyclin D1 in diagnosis]. (12417084)
2002
42
Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. (10942246)
2000
43
Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. (11035575)
2000
44
Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. (11193469)
2000
45
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. (10673747)
2000
46
Expression of cell cycle regulating proteins in an unusual transformation of mantle cell lymphoma. (10613457)
1999
47
Quantitative RNA slot-blot analysis of CCND1/cyclin D1 expression in suspected mantle cell lymphoma. (9436924)
1998
48
bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. (8774476)
1996
49
Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues. (8526214)
1995
50
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. (7595744)
1995

Variations for Mantle Cell Lymphoma

About this section

Copy number variations for Mantle Cell Lymphoma from CNVD:

6 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
14497810660000012200000LossMantle cell lymphoma
24910311102900000110400000LossACATMantle cell lymphoma
34910411102900000110400000LossATMMantle cell lymphoma
44910511102900000110400000LossCUL5Mantle cell lymphoma
54910611102900000110400000LossFDX1Mantle cell lymphoma
64910711102900000110400000LossNPATMantle cell lymphoma
74910811102900000110400000LossRAB39Mantle cell lymphoma
84970311110400000112500000LossMantle cell lymphoma
94999011112500000114500000LossTMPRSS5Mantle cell lymphoma
104999111112500000114500000LossUSP28Mantle cell lymphoma
114999211112500000114500000LossZW10Mantle cell lymphoma
1254401114350000048800000LossTP53I11Mantle cell lymphoma
1360881119280000097200000LossMAML2Mantle cell lymphoma
14612621197200000102100000LossBIRC2Mantle cell lymphoma
15612631197200000102100000LossBIRC3Mantle cell lymphoma
167417613101700000104800000LossBIVMMantle cell lymphoma
177417713101700000104800000LossERCC5Mantle cell lymphoma
187417813101700000104800000LossKDELC1Mantle cell lymphoma
197469413110300000115169878LossC13orf11Mantle cell lymphoma
207469513110300000115169878LossC13orf17Mantle cell lymphoma
217469613110300000115169878LossCUL4AMantle cell lymphoma
227469713110300000115169878LossGRTP1Mantle cell lymphoma
23746983117011831117647068LossLAMPMantle cell lymphoma
247469913110300000115169878LossTFDP1Mantle cell lymphoma
2577990134887788349056026DeletionRB1Mantle cell lymphoma
2679883137900000095000000Copy numbermiR-17-92Mantle cell lymphoma
27809251399300000101700000LossPCCAMantle cell lymphoma
281181151775717207590868MutationP53Mantle cell lymphoma
291414322210288771210598834DeletionMAP2Mantle cell lymphoma
301435122237300000243199373LossMantle cell lymphoma
311708523160700000167600000LossSLITRK3Mantle cell lymphoma
322451729102600000108200000LossINVSMantle cell lymphoma
332488379137400000141213431LossTRAF2Mantle cell lymphoma
3425073492196775121994490DeletionCDKN2AMantle cell lymphoma
3525271493630000038400000LossMELKMantle cell lymphoma
3625474796870000072200000LossTJP2Mantle cell lymphoma
3725630999180000093900000LossDIRAS2Mantle cell lymphoma
38256992999300000102600000LossGPR51Mantle cell lymphoma
39256993999300000102600000LossTBC1D2Mantle cell lymphoma

Expression for genes affiliated with Mantle Cell Lymphoma

About this section
Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for genes affiliated with Mantle Cell Lymphoma

About this section

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 44)
idSuper pathwaysScoreTop Affiliating Genes
110.0MDM2, MYC, TP53
29.9ATM, CCND1, MTOR, MYC
3
Show member pathways
9.9ATM, MDM2, MTOR, TP53
49.9BCL2, CCND1, MYC, TP53
59.9CCND1, MDM2, MYC, TP53
69.9CCND1, CCND2, CCND3, MYC
79.8ATM, CCND3, MCL1, MYC
8
Show member pathways
9.8ATM, BCL2, CCND1, MDM2, TP53
9
Show member pathways
9.8ATM, BCL6, PMAIP1, TP53
109.8BCL2, BMI1, MDM2, MTOR, TP53
119.8BCL6, CD19, CD5, MME
12
Show member pathways
9.8ATM, BCL6, CCND1, CCND2, MDM2
13
Show member pathways
9.8ATM, CCND1, CCND2, CCND3, TP53
149.8ATM, CCND1, CCND2, CCND3, TP53
159.8CCND1, MDM2, MTOR, MYC, TP53
169.8CCND1, MDM2, MTOR, MYC, TP53
17
Show member pathways
9.8CCND1, MDM2, MTOR, MYC, TP53
189.8CCND1, MDM2, MTOR, MYC, TP53
199.7ATM, CCND1, CCND3, MYC, TP53
209.7BCL2, CD19, MDM2, MYC, TP53
219.7CCND1, CCND3, MDM2, MYC, TP53
22
Show member pathways
9.7BCL2, CCND2, CCND3, MTOR, MYC
239.7BMI1, CCND2, MYC, PMAIP1, TP53
249.6ATM, CCND1, CCND2, CCND3, MDM2, TP53
259.6BCL2, CCND1, MDM2, MTOR, MYC, TP53
26
Show member pathways
9.6BCL2, CCND1, MDM2, MTOR, MYC, TP53
27
Show member pathways
9.6ATM, BCL2, MDM2, MYC, PMAIP1, TP53
289.6ATM, CCND1, CCND2, CCND3, MYC, TP53
29
Show member pathways
9.6ATM, BCL2, CCND1, CCND2, MDM2, MTOR
309.6CCND1, CCND2, CCND3, MDM2, PMAIP1, TP53
319.6ATM, BCL2, CCND1, EZH2, MDM2, MYC
329.5ATM, BCL2, CCND1, MDM2, MTOR, MYC
339.5BCL2, BCL6, MCL1, MDM2, PMAIP1, TP53
34
Show member pathways
9.5ATM, CCND1, CCND2, CCND3, MDM2, MYC
359.5ATM, CCND1, CCND2, CCND3, MDM2, MYC
36
Show member pathways
9.5ATM, CCND1, CCND2, CCND3, MDM2, MYC
379.4ATM, BCL6, BMI1, CCND2, MDM2, MYC
38
Show member pathways
9.4ATM, BCL2, MCL1, MDM2, MYC, PMAIP1
39
Show member pathways
9.4CCND1, CCND2, CCND3, MDM2, MTOR, MYC
40
Show member pathways
9.3CCND1, CCND2, CCND3, IGH, MDM2, MTOR
41
Show member pathways
9.2ATM, BCL2, CCND1, CCND2, CCND3, MDM2
429.0ATM, BCL2, BMI1, CCND1, CCND2, EZH2
439.0BCL2, CCND1, CCND2, CCND3, CD19, MCL1
44
Show member pathways
8.7ATM, BCL2, BTK, CCND1, CCND2, CCND3

GO Terms for genes affiliated with Mantle Cell Lymphoma

About this section

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein kinase holoenzyme complexGO:000030710.7CCND1, CCND2, CCND3
2mitochondrial outer membraneGO:000574110.4BCL2, MCL1, MTOR, PMAIP1
3nucleoplasmGO:00056548.4ATM, BCL6, BMI1, CCND1, CCND2, CCND3
4cytoplasmGO:00057378.4ATM, BCL2, BMI1, BTK, CCND1, CCND3
5nucleusGO:00056348.1ATM, BCL2, BCL6, BMI1, BTK, CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 39)
idNameGO IDScoreTop Affiliating Genes
1determination of adult lifespanGO:000834010.9ATM, TP53
2positive regulation of neuron maturationGO:001404210.9BCL2, MTOR
3positive regulation of glial cell proliferationGO:006025210.9MTOR, MYC
4re-entry into mitotic cell cycleGO:000032010.8CCND1, MYC
5mitotic G1 DNA damage checkpointGO:003157110.8CCND1, TP53
6response to steroid hormoneGO:004854510.7BCL2, CCND1, MDM2
7positive regulation of histone deacetylationGO:003106510.7BCL6, TP53
8positive regulation of cell cycleGO:004578710.7CCND1, MDM2, MYC
9cellular response to organic substanceGO:007131010.7BCL2, CCND1, MDM2
10liver regenerationGO:009742110.7CCND1, EZH2, MYC
11DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.7ATM, MDM2, TP53
12positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:190074010.7BCL2, PMAIP1, TP53
13positive regulation of DNA damage response, signal transduction by p53 class mediatorGO:004351710.7ATM, PMAIP1
14response to X-rayGO:001016510.7CCND1, PMAIP1, TP53
15oocyte developmentGO:004859910.6ATM, BCL2
16positive regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573710.6CCND1, CCND2, CCND3
17replicative senescenceGO:009039910.6ATM, MME, TP53
18regulation of mitochondrial membrane permeabilityGO:004690210.6BCL2, PMAIP1, TP53
19cellular response to glucose starvationGO:004214910.6BCL2, PMAIP1, TP53
20B cell receptor signaling pathwayGO:005085310.6BCL2, BTK, CD19
21response to gamma radiationGO:001033210.5BCL2, MYC, TP53
22negative regulation of fibroblast proliferationGO:004814710.5MYC, PMAIP1, TP53
23cell agingGO:000756910.5BCL2, MTOR, TP53
24intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.5ATM, BCL2, MCL1, PMAIP1
25positive regulation of neuron apoptotic processGO:004352510.5ATM, PMAIP1, TP53
26positive regulation of protein phosphorylationGO:000193410.4CCND1, CCND2, CCND3, MTOR
27positive regulation of intrinsic apoptotic signaling pathwayGO:200124410.4BCL2, PMAIP1, TP53
28cell cycle arrestGO:000705010.3ATM, MTOR, MYC, TP53
29negative regulation of gene expressionGO:001062910.3EZH2, MDM2, MYC, SOX11
30regulation of cell cycleGO:005172610.2ATM, BCL2, CCND1, CCND2, CCND3
31regulation of apoptotic processGO:004298110.1ATM, BCL2, BCL6, PMAIP1, TP53
32response to iron ionGO:001003910.0BCL2, CCND1, MDM2
33cellular response to hypoxiaGO:007145610.0BCL2, MDM2, MTOR, PMAIP1, TP53
34regulation of gene expressionGO:00104689.9BCL2, BMI1, EZH2, MDM2, MYC
35negative regulation of apoptotic processGO:00430669.8BCL2, BCL6, MCL1, MDM2, MYC, TP53
36cellular response to DNA damage stimulusGO:00069749.8ATM, BCL2, BCL6, CCND1, MYC, PMAIP1
37positive regulation of cell proliferationGO:00082849.8BCL2, CCND1, MDM2, MYC, SOX11
38cell proliferationGO:00082839.8BCL2, CD5, MYC, SOX11, TP53
39negative regulation of transcription from RNA polymerase II promoterGO:00001229.0BCL6, BMI1, CCND1, EZH2, MDM2, MYC

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1BH3 domain bindingGO:005143410.9BCL2, MCL1
2sequence-specific DNA bindingGO:004356510.0BCL2, BCL6, EZH2, MYC, TP53
3protein kinase bindingGO:001990110.0CCND1, CCND2, CCND3, MTOR, TP53
4protein bindingGO:00055157.7ATM, BCL2, BCL6, BMI1, BTK, CCND1

Sources for Mantle Cell Lymphoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet